APAC Testosterone Replacement Therapy Market

The size of the Testosterone Replacement Therapy Market in the Asia Pacific is estimated to witness a prominent CAGR from 2023 to 2028.

An increase in the frequency of testosterone insufficiency, an increase in the geriatric population at high risk of testosterone shortage, and increasing knowledge about testosterone substitution therapy are driving the Asia pacific testosterone replacement therapy market. In addition, the rising incidence of testosterone deficiency and Hormonal imbalance ailments, such as menopause, are likely to boost the Asia Pacific testosterone replacement treatment market.

The use of testosterone replacement therapy is on the rise, which is propelling the market forward. Furthermore, the market is being pushed by an aging population, which increases the danger of testosterone insufficiency. Hypogonadism affects more than 20.7 percent of diabetic patients globally, according to a study published in the Indian Journal of Endocrinology and Metabolism, especially those aged 40 to 79.

Hypogonadism is a hormonal imbalance in which the body cannot create enough testosterone. Topical testosterone is a medicine applied to the skin to treat the ailment. Topically applied testosterone medicine formulations include creams, gels, and patches.

Increased awareness of testosterone substitution therapy is propelling the Testosterone Replacement Therapy market in the Asia Pacific. In addition, the Endocrine Society established clinical practice recommendations on testosterone therapy to raise awareness of hypogonadism among medical practitioners. These factors are driving the market in the Asia Pacific region.

However, the Asia pacific testosterone replacement therapy market's growth pace is slowed by side effects connected with testosterone replacement therapies. Furthermore, market expansion in emerging countries is hampered by a lack of public awareness and infrastructure. The FDA's tight guidelines governing the use of testosterone medicines are stifling market expansion.

Because coronavirus spreads quickly through human-to-human contact, countries across APAC have implemented lockdowns. The Asian Pacific economy has been severely harmed due to the shutdown. Due to declining estrogen levels, older women are at a higher risk of disease. Furthermore, the absence of hormones may hasten the virus's spread throughout the body. The countries concentrated on primary services, ignoring all non-essential medical services, causing the market to stall. During the epidemic, the market is being hampered by a shortage of hospital facilities.

This research report on the APAC TRT market has been segmented & sub-segmented into the following categories:

By Product Type:

• Patches    
• Injections
• Adhesives               
• Implants  
• Oral        

By Active Ingredient:

• Testosterone Undecanoate            
• Testosterone Enanthate   
• Testosterone Cypionate   
• Methyl Testosterone        

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Asia-Pacific is the third-largest market for testosterone replacement therapy in terms of revenue. Testosterone Replacement Therapy is becoming more common in emerging countries due to its large populations and increased awareness. The Asia Pacific is expected to develop at the fastest rate throughout the forecast period due to a large population and changing lifestyles. The Hormone Replacement Therapy Guidelines of the Japan Society of Obstetrics and Gynaecology and the Japan Society for Menopause and Women's Health were amended in 2012. People were asked about their thoughts on HRT to feel more at ease with the procedure.

In Indonesia, hormones such as testosterone, oestradiol, estrogen, estriol, and progesterone are utilized in bioidentical hormone replacement therapy. Indonesia's market growth is expected to be boosted by the availability of HRT centers in the country. Androgen is the most common testosterone treatment medicine, according to an article. Healthcare professionals' growing awareness and increased attention on removing hormonal shortages are expected to drive market expansion in nations like Malaysia, Bangladesh, and Bhutan. In addition, the increased demand for hormone replacement therapy to treat dwarfism and innovations in drug delivery technology and postmenopausal diseases in women are helping these countries grow their markets.

KEY MARKET PLAYERS:

Companies playing a vital role in the APAC Testosterone Replacement Therapy market covered in this report are Pfizer Inc., Allergan Plc., AbbVie Inc., Bayer AG., Eli Lilly and Company, Endo Pharmaceuticals, Kyowa Kirin International Plc., Novartis AG. and Mylan N.V. among others.